Last reviewed · How we verify
S-1, Bevacizumab
S-1, Bevacizumab is a Small molecule drug developed by Taiho Pharmaceutical Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | S-1, Bevacizumab |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (PHASE1, PHASE2)
- ONO-4538 Phase II Rollover Study (ONO-4538-98) (PHASE2)
- Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites (PHASE2)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis (PHASE2)
- Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma
- Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-1, Bevacizumab CI brief — competitive landscape report
- S-1, Bevacizumab updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about S-1, Bevacizumab
What is S-1, Bevacizumab?
S-1, Bevacizumab is a Small molecule drug developed by Taiho Pharmaceutical Co., Ltd..
Who makes S-1, Bevacizumab?
S-1, Bevacizumab is developed by Taiho Pharmaceutical Co., Ltd. (see full Taiho Pharmaceutical Co., Ltd. pipeline at /company/taiho-pharmaceutical-co-ltd).
What development phase is S-1, Bevacizumab in?
S-1, Bevacizumab is in Phase 2.
Related
- Manufacturer: Taiho Pharmaceutical Co., Ltd. — full pipeline
- Compare: S-1, Bevacizumab vs similar drugs
- Pricing: S-1, Bevacizumab cost, discount & access